Ultragenyx Pharmaceutical Inc. - 2013 Form 10-K Summary
Business Context and Reporting Period
Company: Ultragenyx Pharmaceutical Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2013
Business Overview: Ultragenyx is a development-stage biopharmaceutical company focused on identifying, acquiring, developing, and commercializing novel products for rare and ultra-rare metabolic genetic diseases. The company operates in a single segment and has no approved products or product revenue to date. Its strategy involves in-licensing product candidates and developing them in parallel, with a focus on enzyme replacement therapies and substrate replacement therapies.
Key Financial Metrics (Year Ended Dec 31, 2013)
| Metric | 2013 Value | 2012 Value |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(35.1) million | $(16.3) million |
| Research & Development Expenses | $27.8 million | $12.6 million |
| General & Administrative Expenses | $4.5 million | $3.3 million |
| Cash, Cash Equivalents & Short-Term Investments | $53.4 million | $86.2 million |
| Working Capital | $49.3 million | $83.3 million |
| Total Assets | $59.6 million | $88.3 million |
| Cumulative Net Loss (Inception to 2013) | $(59.6) million | $(24.0) million |
Note: The company had no debt as of December 31, 2013. Convertible promissory notes were converted to preferred stock in 2011.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss more than doubled from $16.3 million in 2012 to $35.1 million in 2013, driven primarily by a 120% increase in R&D expenses.
- R&D Expense Surge: R&D expenses rose by $15.2 million. Key drivers included:
- Triheptanoin (LC-FAOD): $5.2 million increase due to clinical program initiation and option exercise fees.
- Triheptanoin (Glut1 DS): $2.4 million increase for startup costs and drug production.
- rhGUS: $4.0 million increase for process development, manufacturing, and clinical activities.
- KRN23: $0.8 million increase related to collaboration costs with Kyowa Hakko Kirin.
- Cash Position: Cash and short-term investments decreased by approximately $32.8 million, primarily due to operating losses and significant purchases of short-term investments ($64.0 million) offset by maturities ($16.6 million).
- Other Expense: Increased by $2.7 million due to the fair value remeasurement of convertible preferred stock warrant liabilities.
Guidance, Outlook, and Risks
Outlook and Capital Resources:
- The company expects to continue incurring significant losses for the foreseeable future.
- As of December 31, 2013, the company held $53.4 million in cash. Following an Initial Public Offering (IPO) in February 2014 (subsequent to the reporting period), the company received net proceeds of approximately $121.7 million.
- Management believes existing resources, including IPO proceeds, are sufficient to fund operations into 2016.
Product Pipeline Status:
- KRN23 (XLH): Collaboration with Kyowa Hakko Kirin; Phase 1/2 adult data supportive; Phase 2 pediatric study planned for 2014.
- rhGUS (MPS 7): Phase 1/2 study initiated in December 2013; interim data expected in 2014.
- Triheptanoin (LC-FAOD & Glut1 DS): Phase 2 studies ongoing; data expected in 2015.
- SA-ER (HIBM): Phase 2 extension study ongoing; data expected late 2014.
Key Risks:
- Development Risk: No products are approved; clinical trials may fail to demonstrate safety or efficacy.
- Capital Requirements: Significant additional funding will be required for commercialization; future financing may not be available on acceptable terms.
- Third-Party Reliance: Reliance on contract manufacturers and collaborators (e.g., Kyowa Hakko Kirin) for supply and development.
- Intellectual Property: Limited patent coverage for some candidates (e.g., rhGUS, rhPPCA); reliance on orphan drug exclusivity.
Investor Verification Checklist
- Capital Runway: Verify the actual cash balance post-IPO and the burn rate to confirm the "into 2016" funding timeline.
- Clinical Milestones: Monitor the release of Phase 2 pediatric data for KRN23 and Phase 1/2 data for rhGUS in 2014 as critical value drivers.
- Collaboration Terms: Review the specific cost-sharing and profit-sharing mechanics of the Kyowa Hakko Kirin agreement for KRN23.
- Regulatory Pathways: Confirm FDA and EMA acceptance of study designs, particularly for the pivotal studies in ultra-rare diseases (MPS 7, Glut1 DS).
- Manufacturing Capacity: Assess the scalability of third-party manufacturers for commercial launch, given the company has no internal manufacturing facilities.